Aastrom Biosciences will pay Sanofi $6.5m (EUR4.7m) for its cell therapy business in a deal that gives the cash strapped regenerative medicines developer three commercial products.
Catalent will provide Hisun Pharmaceuticals with cell lines to help it develop infliximab, adalimumab and alemtuzumab biosimilars for the Chinese market.
Stem cell company ReNeuron will move its operations and headquarters to Cardiff, UK after leasing an R&D and manufacturing facility from the Welsh government.
Small-sized Australian biopharma developers will be able to use a GMP cell line contract manufacturing facility operated by Patheon Biologics (formerly DSM Biologics) as a result of a AUS$2m (US$1.8m) grant fund.
CMO Cytovance Biologics is extending its manufacturing agreement with Precision Biologics to advance clinical trials with its leading monoclonal antibody candidate, which is being developed as a therapeutic candidate for pancreatic and colorectal cancers....
In what may be an early indication of states looking to get more involved in biologic development, EMD Millipore has won a $400,000 grant from the Massachusetts Life Sciences Center (MLSC) to fund a partnership with Promethera Biosciences.
Bayer is investing over €500m ($700m) in manufacturing recombinant factor VIII (rFVIII) products citing growing demand for long-term prophylactic treatment rather than ‘on-demand’ haemophilia drugs.
GE Healthcare has launched a new cell culture medium that it claims will let manufacturers skip lengthy validation steps and achieve greater batch to batch consistency.
AB Sciex has launched what it claims is the first commercially available ultra-low flow electrospray ionization instrument that links CE (capillary electrophoresis) technology to mass spectrometry.
Cobra Biologics is looking for more scientists with plasmid production skills after BioCancell became the fifth firm in a year to ask the CMO to manufacture a DNA-based gene therapy candidate.
Uptake in single-use is “off the charts” but there is still a growing market for traditional stainless steel technology, says Pall following its acquisition of ATMI.
GE Healthcare has received patent approval for a system which prevents illegal manufacturing and unauthorized operation of disposable bioprocess components.
CMO Cytovance Biologics has entered into a manufacturing agreement with Pamlico Biopharma to develop a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.
GSK has unveiled designs for the £350m ($587m) biomanufacturing plant it intends to build in UK and confirmed that construction will start early next year.
German regulators have approved a 3D manufacturing process that Pluristem Therapeutics claims can produce cell therapies faster and more cheaply than standard methods.
The end of Lonza’s biosimilar joint venture with Teva will not affect manufacturing capacity, the firm says, as it reports a drop in overall revenue for 2013.
US defence contractor Nanotherapeutics will use a modular biomanufacturing system provided by GE Healthcare at a facility it is building in Alachua, Florida.
Buying ATMI will help Pall fill gaps in its up and downstream biomanufacturing tech offerings but the deal does not rule out other acquisitions says CEO, Larry Kingsley
Shire has divested its regenerative skingraft product Dermagraft to Organogenesis citing a loss of financial incentive due to new Medicare ruling regarding reimbursement.
Lonza has signed a five year deal to provide exclusive biologics development and manufacturing services for biotech firms within Index Ventures portfolio.
Sartorius has confirmed it will make the Ambr microreactor technology it acquired with Tap Biosystems compatible with its own downstream processing systems.
Cellexus has launched a new bioreactor system that employs an air-based mixing system that is better at aerating cell cultures than rocking or large chamber systems.
The European Commission (EC) has cleared Thermo Fisher’s acquisition of Life Technologies subject to certain divestitures including its media and sera for cell culture business.
Genentech has recommissioned plans to make a Californian facility the largest biologics plant worldwide after anticipated revenue drop from biosimilars did not materialise.
Orgenesis has partnered ATMI and established a subsidiary in Belgium in order to manufacture cells for clinical trials of its insulin-producing regenerative drug.
ATMI has started exploring strategic alternatives but insists that its bioreactor business is positioned to benefit from increasing biopharma demand for single-use techs.
US biopharma company Repligen has completed a 9,000 square foot expansion of its facilities in Massachusetts to meet growing customer demand for disposable chromatography columns and warehousing.
